[ 18 F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease

Neuropathological stageing of Alzheimer-related changes.

Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×

Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496

Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease

Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668

Neurodegenerative Tauopathies

Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480

Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders

Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065

Alzheimer’s Dementia

Melnick, V. L., & Dubler, N. N. (1985) · Contemporary Issues in Biomedicine, Ethics, and Society · doi:10.1007/978-1-4612-5174-3 · Cited by 1,986

Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP

Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611

The diagnosis of progressive supranuclear palsy: current opinions and challenges

Ali, F., & Josephs, K. A. (2018) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2018.1489241 · Cited by 27

Neuroimaging Biomarkers of Chronic Traumatic Encephalopathy: Targets for the Academic Memory Disorders Clinic

Alosco, M. L., Culhane, J. E., & Mez, J. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01028-3 · Cited by 32

Combined Model of Aggregation and Network Diffusion Recapitulates Alzheimer's Regional Tau-Positron Emission Tomography

Raj, A., Tora, V., Gao, X., Cho, H., Choi, J. Y., Ryu, Y. H., Lyoo, C. H., & Franchi, B. (2021) · Brain Connectivity · doi:10.1089/brain.2020.0841 · Cited by 27

PET Imaging in Animal Models of Alzheimer’s Disease

Chen, B., Marquez-Nostra, B. V., Belitzky, E., Toyonaga, T., Tong, J., Huang, Y. H., & Cai, Z. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.872509 · Cited by 27

Evaluation of [18F]N-methyl-lansoprazole as a tau PET imaging agent in first-in-human studies

Kramer, V., Brooks, A. F., Haeger, A., Kuljiš, R., Rafique, W., Koeppe, R., Raffel, D., Frey, K., Amaral, H., Scott, P., et al. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00639 · Cited by 25

Interaction of APOE4 alleles and PET tau imaging in former contact sport athletes

Vasilevskaya, A., Taghdiri, F., Burke, C., Tarazi, A., Naeimi, S. A., Khodadadi, M., Goswami, R., Sato, C., Grinberg, M., Moreno, D., et al. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102212 · Cited by 27

Development and interval testing of a naturalistic driving methodology to evaluate driving behavior in clinical research

Babulal, G. M., Addison, A., Ghoshal, N., Stout, S. H., Vernon, E. K., Sellan, M., & Roe, C. M. (2016) · F1000Research · doi:10.12688/f1000research.9150.1 · Cited by 26

Face recognition from research brain PET: An unexpected PET problem

Schwarz, C. G., Kremers, W. K., Lowe, V. J., Savvides, M., Gunter, J. L., Senjem, M. L., Vemuri, P., Kantarci, K., Knopman, D. S., Petersen, R. C., et al. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119357 · Cited by 25

18 F-AV-1451 PET Imaging in Three Patients with Probable Cerebral Amyloid Angiopathy

Kim, Y. J., Cho, H., Werring, D. J., Jang, Y. K., Kim, Y. J., Lee, J. S., Lee, J., Jun, S., Park, S., Ryu, Y. H., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161139 · Cited by 26

Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT

Declercq, L., Vandenberghe, R. R., Laere, K. V., Verbruggen, A., & Bormans, G. M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00088 · Cited by 27

Bezafibrate Exerts Neuroprotective Effects in a Rat Model of Sporadic Alzheimer’s Disease

Lin, L., Jhao, Y.-T., Chiu, C., Sun, L.-H., Chou, T.-K., Shiue, C., Cheng, C., & Ma, K. (2022) · Pharmaceuticals · doi:10.3390/ph15020109 · Cited by 27

Insight into the Binding of First- and Second-Generation PET Tracers to 4R and 3R/4R Tau Protofibrils

Li, J., Kumar, A., Långström, B., Nordberg, A. K., & Ågren, H. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00437 · Cited by 25

Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer’s Disease

Lai, R. Y. K., Harrington, C. R., & Wischik, C. M. (2016) · Biomolecules · doi:10.3390/biom6020019 · Cited by 24

Characterization of the radiolabeled metabolite of tau PET tracer 18F-THK5351

Harada, R., Furumoto, S., Tago, T., Furukawa, K., Ishiki, A., Tomita, N., Iwata, R., Tashiro, M., Arai, H., Yanai, K., et al. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3453-y · Cited by 25

An updated radiosynthesis of [18F]AV1451 for tau PET imaging

Mossine, A. V., Brooks, A. F., Henderson, B. D., Hockley, B. G., Frey, K. A., & Scott, P. J. H. (2017) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-017-0027-7 · Cited by 25

Parametric methods for [ 18 F]flortaucipir PET

Golla, S. S. V., Wolters, E. E., Timmers, T., Ossenkoppele, R., van der Weijden, C. W. J., Scheltens, P., Schwarte, L. A., Mintun, M. A., Devous, M. D., Schuit, R. C., et al. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18820765 · Cited by 25

Multi-Modal Signatures of Tau Pathology, Neuronal Fiber Integrity, and Functional Connectivity in Traumatic Brain Injury

Wooten, D., Ortiz-Terán, L., Zubcevik, N., Zhang, X., Huang, C., Sepulcre, J., Atassi, N., Johnson, K. A., ZAFONTE, R. D., & Fakhri, G. E. (2019) · Journal of Neurotrauma · doi:10.1089/neu.2018.6178 · Cited by 26

Classification of Clinically Diagnosed Alzheimer’s Disease Associated with Diabetes Based on Amyloid and Tau PET Results

Takenoshita, N., Shimizu, S., Kanetaka, H., Sakurai, H., Suzuki, R., Miwa, T., Odawara, M., Ishii, K., Shimada, H., Higuchi, M., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190620 · Cited by 24

Neurofibrillary tau depositions emerge with subthreshold cerebral beta-amyloidosis in down syndrome

Zammit, M. D., Tudorascu, D., Laymon, C. M., Hartley, S. L., Ellison, P. A., Zaman, S. H., Ances, B. M., Johnson, S. C., Stone, C. K., Sabbagh, M. N., et al. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102740 · Cited by 25

Dissecting the Binding Profile of PET Tracers to Corticobasal Degeneration Tau Fibrils

Zhou, Y., Li, J., Nordberg, A. K., & Ågren, H. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00536 · Cited by 24

Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective

Ricci, M., Cimini, A., Camedda, R., Chiaravalloti, A., & Schillaci, O. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222313002 · Cited by 24

Early tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression

Kotari, V., Southekal, S. S., Navitsky, M. A., Kennedy, I. A., Lu, M., Morris, A., Zimmer, J. A., Fleisher, A., Mintun, M. A., Devous, M. D., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01160-6 · Cited by 25

Interactions between Microtubule-Associated Protein Tau (MAPT) and Small MoleculesPreprint

Rauch, J. N., Olson, S. H., & Gestwicki, J. E. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024034 · Cited by 22

Ligands for Protein Fibrils of Amyloid-β, α-Synuclein, and Tau

Chisholm, T. S., & Hunter, C. A. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00838 · Cited by 26

Multimodal correlation of dynamic [18F]-AV-1451 perfusion PET and neuronal hypometabolism in [18F]-FDG PET

Hammes, J., Leuwer, I., Bischof, G. N., Drzezga, A. E., & van Eimeren, T. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3840-z · Cited by 23

Progress regarding the context-of-use of tau as biomarker of Alzheimer’s disease and other neurodegenerative diseases

Campese, N., Palermo, G., Gamba, C. D., Beatino, M. F., Galgani, A., Belli, E., Prete, E. D., Vecchia, A. D., Vergallo, A., Siciliano, G., et al. (2021) · Expert Review of Proteomics · doi:10.1080/14789450.2021.1886929 · Cited by 23

Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer’s disease

Hajjar, I. M., Okafor, M. O., Wan, L., Yang, Z., Nye, J. A., Bohsali, A. A., Shaw, L. M. J., Levey, A. I., Lah, J. J., Calhoun, V. D., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac270 · Cited by 24

In Silico Discovery and Subsequent Characterization of Potent 4R-Tauopathy Positron Emission Tomography Radiotracers

Graham, T. J. A., Lindberg, A., Tong, J., Stehouwer, J. S., Vasdev, N., Mach, R. H., & Mathis, C. A. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00775 · Cited by 22

[ 18 F]AV‐1451 binding is increased in frontotemporal dementia due to C9orf72 expansion

Bevan-Jones, W. R., Cope, T., Jones, S. P., Passamonti, L., Hong, Y. T., Fryer, T. D., Arnold, R. J., Coles, J., Aigbirhio, F. A., Patterson, K. E., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.631 · Cited by 26

Tau PET Imaging for Staging of Alzheimer's Disease in Down Syndrome

Rafii, M. S. (2018) · Developmental Neurobiology · doi:10.1002/dneu.22658 · Cited by 23

Novel PET/SPECT Probes for Imaging of Tau in Alzheimer’s Disease

Watanabe, H., Ono, M., & Saji, H. (2015) · The Scientific World JOURNAL · doi:10.1155/2015/124192 · Cited by 22

Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia

Eisenmenger, L. B., Huo, E. J., Hoffman, J. M., Minoshima, S., Matesan, M. C., Lewis, D. H., Lopresti, B. J., Mathis, C. A., Okonkwo, D. O., & Mountz, J. M. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2015.09.003 · Cited by 21

Molecular Imaging of Fluorinated Probes for Tau Protein and Amyloid-β Detection

Yeo, S. K., Shepelytskyi, Y., Grynko, V., & Albert, M. S. (2020) · Molecules · doi:10.3390/molecules25153413 · Cited by 22

1H MR spectroscopy biomarkers of neuronal and synaptic function are associated with tau deposition in cognitively unimpaired older adults

Kara, F., Joers, J. M., Deelchand, D. K., Park, Y. W., Przybelski, S. A., Lesnick, T. G., Senjem, M. L., Zeydan, B., Knopman, D. S., Lowe, V. J., et al. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.12.010 · Cited by 22

Head-to-Head Comparison of Tau-PET Radioligands for Imaging TDP-43 in Post-Mortem ALS Brain

Knight, A. C., Morrone, C. D., Varlow, C., Yu, W. H., Mcquade, P. S., & Vasdev, N. (2022) · Molecular Imaging and Biology · doi:10.1007/s11307-022-01779-1 · Cited by 23

Thiophene‐Based Ligands: Design, Synthesis and Their Utilization for Optical Assignment of Polymorphic‐Disease‐Associated Protein Aggregates

Björk, L., Klingstedt, T., & Nilsson, K. P. R. (2023) · ChemBioChem · doi:10.1002/cbic.202300044 · Cited by 24

Detection and Characterization of Small Molecule Interactions with Fibrillar Protein Aggregates Using Microscale Thermophoresis

Fisher, E., Zhao, Y., Richardson, R., Janik, M. A., Buell, A. K., Aigbirhio, F. I., & Tóth, G. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00228 · Cited by 22

Relationship Between18F-Flortaucipir Uptake and Histologic Lesion Types in 4-Repeat Tauopathies

Josephs, K. A., Tosakulwong, N., Weigand, S. D., Buciuc, M., Lowe, V. J., Dickson, D. W., & Whitwell, J. L. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262685 · Cited by 24

Chronic Traumatic Encephalopathy

Turk, K. W., & Budson, A. E. (2019) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000686 · Cited by 23

Harnessing the Immune System for Treatment and Detection of Tau Pathology

Congdon, E. E., Krishnaswamy, S., & Sigurdsson, E. M. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132435 · Cited by 20

[18F]THK5351 PET Imaging in Patients with Mild Cognitive Impairment

Jeong, H.-J., Lee, H., Lee, S., Seo, S., Park, K. H., Lee, Y., Shin, D. J., Kang, J. M., Yeon, B. K., Kang, S., et al. (2020) · Journal of Clinical Neurology · doi:10.3988/jcn.2020.16.2.202 · Cited by 20

Update on neuroimaging for categorization of Parkinson's disease and atypical parkinsonism

Chougar, L., Pyatigorskaya, N., & Lehéricy, S. (2021) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000957 · Cited by 20

Tau Protein Binding Modes in Alzheimer’s Disease for Cationic Luminescent Ligands

Todarwal, Y., Gustafsson, C., Minh, N. N. T., Ertzgaard, I., Klingstedt, T., Ghetti, B. F., Vidal, R., König, C., Lindgren, M., Nilsson, K. P. R., et al. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c06019 · Cited by 20

Cognition in movement disorders: Where can we hope to be in ten years?

Burn, D. J., Weintraub, D. A., Ravina, B. M., & Litvan, I. (2014) · Movement Disorders · doi:10.1002/mds.25850 · Cited by 20

PI-2620 Lead Optimization Highlights the Importance of Off-Target Assays to Develop a PET Tracer for the Detection of Pathological Aggregated Tau in Alzheimer’s Disease and Other Tauopathies

Kroth, H., Oden, F., Molette, J., Schieferstein, H., Gabellieri, E., Mueller, A., Berndt, M., Sreenivasachary, N., Serra, A. M., Capotosti, F., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00861 · Cited by 20

New protein deposition tracers in the pipeline

Jovalekic, A., Koglin, N., Mueller, A., & Stephens, A. W. (2016) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-016-0015-3 · Cited by 19

Imaging pathological tau in atypical parkinsonisms: A review

Mena, A. M., & Strafella, A. P. (2022) · Clinical Parkinsonism & Related Disorders · doi:10.1016/j.prdoa.2022.100155 · Cited by 20

Tauopathy promotes spinal cord-dependent production of toxic amyloid-beta in transgenic monkeys

Tu, Z., Yan, S., Han, B., Li, C., Liang, W., Lin, Y., Ding, Y., Wei, H., Wang, L., Xu, H., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01601-6 · Cited by 20

Current status of PET tracers for the early diagnosis of Alzheimer's disease

Li, Y., Liu, T., Zeng, Q., & Cui, M. (2024) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2024.117546 · Cited by 20

Clinical Trials: Past, Current, and Future for Atypical Parkinsonian Syndromes

Boxer, A. L., & Tsai, R. M. (2014) · Seminars in Neurology · doi:10.1055/s-0034-1381739 · Cited by 19

What amyloid ligands can tell us about molecular polymorphism and disease

LeVine, H., & Walker, L. C. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.03.019 · Cited by 19

Identification of Heterogeneous Subtypes of Mild Cognitive Impairment Using Cluster Analyses Based on PET Imaging of Tau and Astrogliosis

Lee, H. J., Lee, E.-C., Seo, S., Ko, K., Kang, J. M., Kim, W., Seo, H., Lee, S.-Y., Lee, Y., Park, K. H., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.615467 · Cited by 19

Key biomarkers in Alzheimer’s disease: Insights for diagnosis and treatment strategies

Jamal, R., Shaikh, M. A., Taleuzzaman, M., Haque, Z., Albratty, M., Alam, M. S., Makeen, H. A., Zoghebi, K. A., & Saleh, S. F. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251330500 · Cited by 19

The Irony of PET Tau Probe Specificity

Barrio, J. R. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.198960 · Cited by 18

Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies

Choi, Y., Ha, S., Lee, Y., Kim, Y. K., Lee, D. S., & Kim, D. J. (2017) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-017-0484-7 · Cited by 18

Tau: a biomarker of Huntington’s disease

Lepinay, E., & Cicchetti, F. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02230-9 · Cited by 19

Early Diagnosis of Neurodegenerative Diseases: What Has Been Undertaken to Promote the Transition from PET to Fluorescence Tracers

Bisi, N., Pinzi, L., Rastelli, G., & Tonali, N. (2024) · Molecules · doi:10.3390/molecules29030722 · Cited by 17

Binding of [18F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients

Schaeverbeke, J. M., Celen, S., Cornelis, J., Ronisz, A., Serdons, K., Laere, K. V., Thal, D. R., Tousseyn, T., Bormans, G. M., & Vandenberghe, R. R. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04631-x · Cited by 19

Synthesis and Assessment of Novel Probes for Imaging Tau Pathology in Transgenic Mouse and Rat Models

McMurray, L., Macdonald, J. A., Ramakrishnan, N. K., Zhao, Y., Williamson, D. W., Tietz, O., Zhou, X., Kealey, S., Fagan, S. G., Smolek, T., et al. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00790 · Cited by 17

Predominant subcortical accumulation of 18 F-flortaucipir binding in behavioral variant frontotemporal dementia

Cho, H., Seo, S. W., Choi, J. Y., Lee, H. S., Ryu, Y. H., Lee, M. S., Na, D. L., Kim, H. J., & Lyoo, C. H. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.02.015 · Cited by 19

Detection of tau in Gerstmann-Sträussler-Scheinker disease (PRNP F198S) by [18F]Flortaucipir PET

Risacher, S. L., Farlow, M. R., Bateman, D. R., Epperson, F., Tallman, E. F., Richardson, R. M., Murrell, J. R., Unverzagt, F. W., Apostolova, L. G., Bonnin, J. M., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0608-z · Cited by 19

Comparative assessment of regional tau distribution by Tau-PET and Post-mortem neuropathology in a representative set of Alzheimer’s & frontotemporal lobar degeneration patients

Gatto, R. G., Carlos, A. F., Reichard, R. R., Lowe, V. J., Whitwell, J. L., & Josephs, K. A. (2023) · PLoS ONE · doi:10.1371/journal.pone.0284182 · Cited by 17

Cortical microstructural changes predict tau accumulation and episodic memory decline in older adults harboring amyloid

Gagliardi, G. P., Rodriguez‐Vieitez, E., Montal, V., Sepulcre, J., Diez, I. P., Lois, C., Hanseeuw, B. J., Schultz, A. P., Properzi, M. J., Papp, K. V., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00324-7 · Cited by 16

Coordination chemistry of ligands: Insights into the design of amyloid beta/tau-PET imaging probes and nanoparticles-based therapies for Alzheimer’s disease

Selvan, S. T., Ravichandar, R., Ghosh, K. K., Mohan, A., Mahalakshmi, P., Gulyás, B. Z., & Padmanabhan, P. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213659 · Cited by 16

Effect of Shortening the Scan Duration on Quantitative Accuracy of [18F]Flortaucipir Studies

Tuncel, H., Visser, D., Yaqub, M. M., Timmers, T., Wolters, E. E., Ossenkoppele, R., van der Flier, W. M., van Berckel, B. N. M., Boellaard, R., & Golla, S. S. V. (2021) · Molecular Imaging and Biology · doi:10.1007/s11307-021-01581-5 · Cited by 16

The Role of Tau Imaging in Parkinsonian Disorders

Hammes, J., Drzezga, A. E., & van Eimeren, T. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0898-3 · Cited by 18

Human Radiation Dosimetry of [18F]AV-1451(T807) to Detect Tau Pathology

Choi, J. Y., Lyoo, C. H., Lee, J., Cho, H., Kim, K. M., Kim, J. S., & Ryu, Y. H. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0924-7 · Cited by 16

Discovery and Evaluation of Imidazo[2,1-b][1,3,4]thiadiazole Derivatives as New Candidates for α-Synuclein PET Imaging

Zeng, Q., Zhang, X., Li, Y., Zhang, Q., Dai, J., Yan, X., Liu, Y., Zhang, J., Liu, S., & Cui, M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00686 · Cited by 15

18 F-Flortaucipir PET Associations with Cerebrospinal Fluid, Cognition, and Neuroimaging in Mild Cognitive Impairment due to Alzheimer’s Disease

Okafor, M. O., Nye, J. A., Shokouhi, M., Shaw, L. M. J., Goldstein, F. C., & Hajjar, I. M. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191330 · Cited by 16

18F-AV-1451 positron emission tomography in neuropathological substrates of corticobasal syndrome

Goodheart, A. E., Locascio, J. J., Samore, W. R., Collins, J. A., Brickhouse, M. J., Schultz, A. P., Touroutoglou, A., Johnson, K. A., Frosch, M. P., Growdon, J. H., et al. (2020) · Brain · doi:10.1093/brain/awaa383 · Cited by 16

Imaging tau pathology in Parkinsonisms

Coakeley, S., & Strafella, A. P. (2017) · npj Parkinson s Disease · doi:10.1038/s41531-017-0023-3 · Cited by 15

Quantum Mechanics/Molecular Mechanics Density Functional Theory Simulations of the Optical Properties Fingerprinting the Ligand-Binding of Pentameric Formyl Thiophene Acetic Acid in Amyloid-β(1–42)

Gustafsson, C., Linares, M., & Norman, P. (2020) · The Journal of Physical Chemistry A · doi:10.1021/acs.jpca.9b09779 · Cited by 15

New PET markers for the diagnosis of dementia

Payoux, P., & Salabert, A. (2017) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000489 · Cited by 14

Synthesis and Preclinical Evaluation of 2-(4-[ 18 F]Fluorophenyl)imidazo[1,2-h][1,7]naphthyridine ([ 18 F]FPND-4): An Aza-Fused Tricyclic Derivative as Positron Emission Tomography Tracer for Neurofibrillary Tangle Imaging

Liu, T., Li, Y., Zhang, X., Yao, A., Wang, Y., Yao, S., Chen, B., Yan, X., Dai, J., Zhang, J., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00239 · Cited by 14

Synthesis and Evaluation of 13N-Labelled Azo Compounds for β-Amyloid Imaging in Mice

Gaja, V., Gómez‐Vallejo, V., Puigivila, M., Pérez‐Campaña, C., Martín, A., García‐Osta, A., Calvo-Fernández, T., Cuadrado‐Tejedor, M., Franco, R., & Llop, J. (2013) · Molecular Imaging and Biology · doi:10.1007/s11307-013-0708-x · Cited by 14

The influence of β-amyloid on [ 18 F]AV-1451 in semantic variant of primary progressive aphasia

Whitwell, J. L., Martin, P. R., Duffy, J. R., Clark, H. M., Machulda, M. M., Schwarz, C. G., Weigand, S. D., Sintini, I., Senjem, M. L., Ertekin‐Taner, N., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000006913 · Cited by 15

MAPT rs242557 variant is associated with hippocampus tau uptake on 18F-AV-1451 PET in non-demented elders

Shen, X., Miao, D., Li, J., Tan, C., Cao, X., Tan, L., & Yu, J. (2019) · Aging · doi:10.18632/aging.101783 · Cited by 14

AD molecular: Imaging tau aggregates with positron emissions tomography

Betthauser, T. J. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.07.007 · Cited by 14

18F-MK-6240 tau PET in patients at-risk for chronic traumatic encephalopathy

Alosco, M. L., Mejía, J. A., Culhane, J. E., Shankar, R. P., Nowinski, C. J., Bureau, S. C., Mundada, N. S., Smith, K., Amuiri, A. N., Asken, B. M., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00808-1 · Cited by 13

Staging Alzheimer’s disease through amyloid and tau PET

Johnson, D. R., Wiste, H. J., Lowe, V. J., Schwarz, C. G., Knopman, D. S., Vemuri, P., Kantarci, K., Boeve, B. F., Graff‐Radford, J., Cogswell, P. M., et al. (2025) · Brain · doi:10.1093/brain/awaf346 · Cited by 13

Pick’s Tau Fibril Shows Multiple Distinct PET Probe Binding Sites: Insights from Computational Modelling

Mishra, S. K., Yamaguchi, Y., Higuchi, M., & Sahara, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010349 · Cited by 14

Strategies of positron emission tomography (PET) tracer development for imaging of tau and α-synuclein in neurodegenerative disorders

Mekala, S., Wu, Y., & Li, Y. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00576g · Cited by 13

Current Progress and Future Directions in Non-Alzheimer’s Disease Tau PET Tracers

Wongso, H., Harada, R., & Furumoto, S. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00319 · Cited by 13

Monoamine oxidase binding not expected to significantly affect [18F]flortaucipir PET interpretation

Wright, J. P., Goodman, J. R., Lin, Y., Lieberman, B. P., Clemens, J., Gomez, L. F., Liang, Q., Hoye, A. T., Pontecorvo, M. J., & Conway, K. A. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05822-9 · Cited by 13

(S)-[18F]THK5117 brain uptake is associated with Aβ plaques and MAO-B enzyme in a mouse model of Alzheimer's disease

Alzghool, O. M., Rokka, J., Lopez‐Picon, F. R., Snellman, A., Helin, J. S., Okamura, N., Solin, O. H., Rinne, J. O., & Haaparanta‐Solin, M. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108676 · Cited by 12

Exosomal Non-Coding RNAs as Potential Biomarkers for Alzheimer’s Disease: Advances and Perspectives in Translational Research

Titze-de-Almeida, S. S., Marina, C. L., Ramos, M. V., Silva, L. D. D. S., Brandão, P. R. D. P., Bispo, D. D. D. C., von Glehn, F., & Titze‐de‐Almeida, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178246 · Cited by 13

Click Chemistry: The Certainty of Chance (Nobel Lecture)**

Sharpless, K. B., Finn, M. G., & Kolb, H. C. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202501229 · Cited by 12

Sex‐ and region‐dependent neuroinflammation in Alzheimer's disease

Acosta‐Martínez, M., Carter, V., Nessim, A., Panchal, R., John, D., Dhawan, J., Beach, T. G., Serrano, G. E., Sundermann, E. E., & Biegon, A. R. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14603 · Cited by 15

Tau and Amyloid Positron Emission Tomography Imaging Predict Driving Performance Among Older Adults with and without Preclinical Alzheimer’s Disease

Roe, C., Babulal, G., Mishra, S., Gordon, B., Stout, S. H., Ott, B. L., Carr, D., Ances, B., Morris, J., & Benzinger, T. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170521 · Cited by 15

Molecular Imaging of Dementia With Lewy Bodies

Cousins, O., Yousaf, T., Wilson, H., Pagano, G., & Politis, M. (2018) · International review of neurobiology · doi:10.1016/bs.irn.2018.10.007 · Cited by 12

Impact of spill-in counts from off-target regions on [18F]Flortaucipir PET quantification

López‐González, F. J., Costoya‐Sánchez, A., Paredes‐Pacheco, J., Moscoso, A., Silva‐Rodríguez, J., & Aguiar, P. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119396 · Cited by 13

Tau-PET abnormality as a biomarker for Alzheimer’s disease staging and early detection: a topological perspective

Ding, J., Shen, C., Wang, Z., Yang, Y., Fakhri, G. E., Lu, J., Liang, D., Zheng, H., Zhou, Y., Sun, T., et al. (2023) · Cerebral Cortex · doi:10.1093/cercor/bhad312 · Cited by 13

Synthesis, characterization, and preclinical validation of a PET radiopharmaceutical for interrogating Aβ (β-amyloid) plaques in Alzheimer’s disease

Sundaram, G. S. M., Dhavale, D. D., Prior, J. L., Sivapackiam, J., Laforest, R. A., Kotzbauer, P. T., & Sharma, V. (2015) · EJNMMI Research · doi:10.1186/s13550-015-0112-4 · Cited by 12

Structure–Activity Relationships of Radioiodinated Benzoimidazopyridine Derivatives for Detection of Tau Pathology

Kaide, S., Ono, M., Watanabe, H., Kitada, A., Yoshimura, M., Shimizu, Y., Ihara, M., & Saji, H. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00092 · Cited by 12

A Closer Look into the Role of Protein Tau in the Identification of Promising Therapeutic Targets for Alzheimer’s Disease

Khan, R. I., Nirzhor, S. S. R., & Rashid, B. (2018) · Brain Sciences · doi:10.3390/brainsci8090162 · Cited by 12

Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms

Lyoo, C. H., Cho, H., Choi, J. Y., Ryu, Y. H., & Lee, M. S. (2018) · Journal of Movement Disorders · doi:10.14802/jmd.17071 · Cited by 12

A single-domain antibody for the detection of pathological Tau protein in the early stages of oligomerization

Leiris, N. D., Perret, P., Lombardi, C., Gözel, B., Chierici, S., Millet, P., Debiossat, M., Bacot, S., Tournier, B. B., Chames, P., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04987-1 · Cited by 10

Chronic traumatic encephalopathy: State-of-the-science update and narrative review

Asken, B. M., Brett, B. L., Barr, W., Banks, S. J., Wethe, J. V., Dams-O’Connor, K., Stern, R. A., & Alosco, M. L. (2025) · The Clinical Neuropsychologist · doi:10.1080/13854046.2025.2454047 · Cited by 12

The development of a PET radiotracer for imaging alpha synuclein aggregates in Parkinson's disease

Tian, G., Hsieh, C., Guarino, D. S., Graham, T. J. A., Lengyel‐Zhand, Z., Schmitz, A. M. T., Chia, W., Young, A. J., Crosby, J.-G., Plakas, K., et al. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00057b · Cited by 11

Synthesis of Naphthalene-Based Push-Pull Molecules with a Heteroaromatic Electron Acceptor

Šarlah, D., Juranovič, A., Kožar, B., Rejc, L., Golobič, A., & Petrič, A. (2016) · Molecules · doi:10.3390/molecules21030267 · Cited by 11

Looking for the link between plaques and tangles

Duyckaerts, C. J. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.014 · Cited by 53

Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807

Chien, D. T., Bahri, S., Szardenings, A. K., Walsh, J. C., Mu, F., Su, M.-Y., Shankle, W. R., Elizarov, A., & Kolb, H. C. (2013) · Journal of Alzheimer's Disease · doi:10.3233/jad-122059 · Cited by 651

A highly selective and specific PET tracer for imaging of tau pathologies

Zhang, W., Arteaga, J., Cashion, D. K., Chen, G., Gangadharmath, U., Gomez, L. F., Kasi, D., Lam, C., Liang, Q., Liu, C., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120712 · Cited by 195

Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808

Chien, D. T., Szardenings, A. K., Bahri, S., Walsh, J. C., Mu, F., Xia, C. A., Shankle, W. R., Lerner, A. J., Su, M., Elizarov, A. M., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130098 · Cited by 683

171 Early Clinical PET Imaging Results with the Novel PHF-Tau Radioligand [F18]-T808

Chiena, D. T., Szardeningsa, A. K., Bahrib, S., Walsha, J. C., Mua, F., Xiaa, C., Shanklec, W. R., Lernerd, A. J., Sub, M.-Y., Elizarova, A., et al. (2013)